Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

In-licensing announced of a novel clinical phase III-ready Exblifep, an oral antibiotic, ceftibuten-ledaborbactam etzadroxil to treat urinary tract infections – Basilea

Written by | 19 Aug 2025

Basilea Pharmaceutica announced that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil (Exblifep), a clinical phase… read more.

FDA approves Blujepa (gepotidacin) for treatment of uncomplicated urinary tract infections in female adults and paediatric patients 12 years of age and older – GSK

Written by | 1 Apr 2025

GSK plc announced that the FDA has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary… read more.

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections – Utility Therapeutics

Written by | 30 Apr 2024

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of… read more.

A myth no more: Cranberry products can prevent urinary tract infections for women

Written by | 23 Apr 2023

Drinking cranberry juice has long been a mythical prevention strategy for women who develop a urinary tract infection – and new medical evidence shows consuming cranberry products is… read more.

Non-antibiotic prophylaxis appears effective for recurrent UTIs

Written by | 3 Jan 2023

Methenamine hippurate could be as effective as antibiotics for preventing recurrent urinary tract infections (UTIs), according to a recent alert from the National Institute for Health and Care… read more.

Shorter course of antibiotics is effective for men with urinary tract infection

Written by | 28 Aug 2021

Researchers report that, for treatment of afebrile (non-feverish) men with a urinary tract infection (UTI), a 7-day course of ciprofloxacin or trimethoprim/sulfamethoxazole is a non-inferior alternative to a… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.